Clinical / Outcomes
On This Page
Electrophysiology and Electrocardiography
- Paul Wang: atrial fibrillation; pacemakers/defibrillators; catheter ablation; hypertrophic cardiomyopathy
- Henry Hsia: ventricular tachycardia: mapping and ablation
- Amin Al-Ahmad: new techniques in catheter ablation of atrial fibrillation
- Paul Zei: ventricular tachycardia mechanisms; atrial Fibrillation mechanisms; new ablation technologies; new device technologies; new mapping techniques
- Victor Froelicher: Exercise physiology: testing and training; risk assessment and prognosis in CAD.
- Karen Friday: Triggers in atrial fibrillation; behavioral cardiology.
Interventional Cardiology and Biotechnology
- Alan Yeung: endothelial dysfunction and vascular remodeling in coronary atherosclerosis (epicardial and microvascular); modification of atherogenesis via local drug delivery; adjunctive pharmacologic treatment in PTCA; clinical trials of new devices.
- William Fearon: His research is funded by the NIH through a K23 Career Development Award. His research focus is coronary physiology. In particular, he is interested in invasive, wire-based techniques for investigating the significance of epicardial coronary artery stenoses and for interrogating the status of the coronary microcirculation. Recently, in an animal model, he validated a novel index for measuring microvascular resistance. He is now coordinating clinical studies to further test the usefulness of this index. He is also applying these techniques in cardiac transplant recipients in hopes of better understanding transplant vasculopathy.
- Simon Sterzer: Intramyocardial delivery of myoblasts and vasculogenic peptides; tissue engineering of autologous blood vessels; retrieval atherectomy in vein grafts and native coronary circulation; drug eluting stent technology development without a polymer base in bare metal stents.
- Paul Yock: His research interests center around new catheter-based technologies for cardiovascular disease. Current work focuses on catheter methods for delivery of genes, proteins, and cells into damaged myocardium, and new catheter-based imaging techniques. Paul York, MD also maintains an active interest in intravascular ultrasound, including participation in the IVUS core laboratory directed by Peter Fitzgerald, MD. He also directs the Biodesign Program, which explores new approaches to invention and technology transfer in the medical device and diagnostic arena.
- Peter J. Fitzgerald: Intravascular ultrasound imaging.
Cardiac Imaging
- David Liang: Medical Imaging, particularly forward-viewing intravascular ultrasound and digital echocardiography; applications of magnetic resonance imaging.
- Phil Yang: Dr. Yang’s research interest focuses on comprehensive diagnosis of ischemic heart disease using cardiac MRI. Novel MR imaging sequences enabling rapid and integrated imaging of the coronary arteries, LV function, perfusion, and viability have been implemented. By combining chemical sensitivity of nuclear magnetic resonance with high sptial and temporal resolution, a wide range of biological events spanning from molecular to physiologic processes can be characterized. Specifically, in vivo MR imaging of stem cell biology and therapeutic effects on peri-infarct ischemia is investigated.
- Michael McConnell: Imaging cardiovascular disease, with a focus on coronary and vascular atherosclerosis and ischemic heart disease. Projects include cellular and structural characterization of atherosclerotic plaque by MRI, optical imaging (bioluminescence and fluorescence) of vascular imflammation, as well as noninvasive coronary angiography by MRI and MRI-guided cardiovascular interventions. Additional collaborative projects include real-time cardiac MRI and multi-modality imaging of cardiac stem cell transplantation. Resonance Systems Research Lab (MRSRL).
- Ingela Schnittger: Echocardiograph y with particular interest in transesophageal echocardiography used as a diagnostic and monitoring tool and exercise/stress echocardiography, using echocardiography with treadmill testing or with pharmacologic.
Heart Failure and Cardiac Transplantation
- Michael B. Fowler: Clinical and laboratory investigation in heart failure.
- Randy Vagelos: Prognosis in congestive heart failure; experimental drug therapy in congestive heart failure.
- Sharon Hunt: Immunosuppression for graft rejection; clinical management of transplant recipients; graft atherosclerosis.
- Hannah A. Valantine: Pathophysiology of transplant coronary vasculopathy focusing on the role of diabetes and CMV infection. Noninvasive diagnosis of cardiac allograft rejection; pathobiology of graft rejection.
- John S. Schroeder: Clinical efficacy of calcium channel blockers for CAD and prevention of transplant coronary vasculopathy; investigations of factors affecting survival following cardiac transplantation.
- Mark Perlroth: Long term follow-up of heart transplantation recipients and adults with congenital heart disease; cyclosporine-induced hypertension and nephropathy; adriamycin cardiotoxicity.
- Euan A. Ashley: Translational research using high dimensional genomic analysis to identify myocardial gene expression networks.
Other Clinical Investigations
- Robert F. DeBusk: Design, evaluate and disseminate disease management systems for chronic diseases including heart failure, coronary heart disease, and hypertension. Special interests include adaptation of distributed information management systems for decision support and creation/validation of psychometric indicators of adherence using the concept of self-efficacy. Active projects include NHLBI and Department of Veterans Affairs - sponsored randomized clinical trials of comprehensive management of heart failure using the MULTIFIT system.
- John Giacomini: Cardiovascular pharmacology as it relates to treatment of hypertension and dyslipidemia.
- William L. Haskell: Clinical trials for primary or secondary prevention of CHD; acute and chronic effects of exercise on CV status; determination and modification of CHD risk factors.
- Randy Vagelos: Markers of coronary ischemia; radiation induced cardiac disease.
- Paul Heidenreich: Quality of care measures in ischemic heart disease and congestive heart failure; cost-effectiveness analysis of cardiovascular interventions; screening for LV systolic dysfunction; echocardiographic predictors of mortality.
- Jonathan Myers: He coordinates the research activities in the exercise laboratory in the Cardiology Division at the VA Palo Alto Health Care System. His research has focused on the areas of exercise training in chronic heart failure, diagnostic and prognostic applications of cardiopulmonary exercise testing, epidemiology related to cardiovascular disease, and cardiovascular health in disabled populations. His currently funded projects include the association between heart rate variability, physical activity patterns, and cardiovascular health, and the cost-effectiveness of an intensive, case-managed risk reduction program in patients at high risk for the development of cardiovascular disease.